H.C. Wainwright lowered the firm’s price target on Legend Biotech to $86 from $87 and keeps a Buy rating on the share following the Q1 report. The firm expects “substantial growth” in the second half of 2024 for the company.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LEGN:
- Legend Biotech’s Strong Q1 Growth and Strategic Expansion
- LEGN Upcoming Earnings Report: What to Expect?
- Legend Biotech participates in a conference call with JPMorgan
- European Approval for Legend Biotech’s Myeloma Treatment
- Legend Biotech says Carvykti approved by EC for second-line multiple myeloma